14 results
10-Q
2021 Q1
MRVI
Maravai LifeSciences Holdings Inc - Ordinary Shares
12 May 21
Quarterly report
4:26pm
customers are developing are early in their lifecycle. We expect an increase in demand for our GMP-grade nucleic acids to the extent that our customers
424B4
MRVI
Maravai LifeSciences Holdings Inc - Ordinary Shares
9 Apr 21
Prospectus supplement with pricing info
4:02pm
of the cell and gene therapy development lifecycle. For example, our mRNA products are used in drug development to assist in the production of immune
DRS
y5sgl8t4nmx3avhtz
25 Mar 21
Draft registration statement
12:00am
10-K
52f5r yr1s2
22 Mar 21
Annual report
4:22pm
424B4
w7warq up
23 Nov 20
Prospectus supplement with pricing info
4:36pm
S-1
iy2ybglxbukd9wa4q
29 Oct 20
IPO registration
5:04pm
DRS/A
7o0 i0vmwze7prey
23 Oct 20
Draft registration statement (amended)
12:00am
DRS/A
4iq8x00pdns
14 Oct 20
Draft registration statement (amended)
12:00am
DRS
e6g2u
8 Sep 20
Draft registration statement
12:00am
- Prev
- 1
- Next